[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse LCP1

Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm, cytoskeleton Cell junction Cell projection Cell projection, ruffle membrane Peripheral membrane protein Cytoplasmic side Note=Relocalizes to the immunological synapse between peripheral blood T-lymphocytes and antibody-presenting cells in response to costimulation through TCR/CD3 and CD2 or CD28 (PubMed:17294403). Associated with the actin cytoskeleton at membrane ruffles. Relocalizes to actin-rich cell projections upon serine phosphorylation (PubMed:16636079).
Domain PF00307 Calponin homology (CH) domain
PF13499 EF-hand domain pair
Function

Actin-binding protein (PubMed:16636079, PubMed:17294403, PubMed:28493397). Plays a role in the activation of T-cells in response to costimulation through TCR/CD3 and CD2 or CD28 (PubMed:17294403). Modulates the cell surface expression of IL2RA/CD25 and CD69 (PubMed:17294403).

> Gene Ontology
 
Biological Process GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0007015 actin filament organization
GO:0007159 leukocyte cell-cell adhesion
GO:0010737 protein kinase A signaling
GO:0022617 extracellular matrix disassembly
GO:0030198 extracellular matrix organization
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031334 positive regulation of protein complex assembly
GO:0032386 regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0042110 T cell activation
GO:0043062 extracellular structure organization
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0051017 actin filament bundle assembly
GO:0051639 actin filament network formation
GO:0051764 actin crosslink formation
GO:0061572 actin filament bundle organization
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0071800 podosome assembly
GO:0071801 regulation of podosome assembly
GO:0071803 positive regulation of podosome assembly
GO:1902115 regulation of organelle assembly
GO:1902117 positive regulation of organelle assembly
Molecular Function GO:0003779 actin binding
GO:0051015 actin filament binding
GO:0051020 GTPase binding
Cellular Component GO:0001725 stress fiber
GO:0001726 ruffle
GO:0001891 phagocytic cup
GO:0002102 podosome
GO:0005884 actin filament
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015629 actin cytoskeleton
GO:0030055 cell-substrate junction
GO:0030175 filopodium
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032432 actin filament bundle
GO:0032587 ruffle membrane
GO:0042641 actomyosin
GO:0097517 contractile actin filament bundle
GO:0098858 actin-based cell projection
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LCP1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LCP1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24009233Chronic Lymphocytic LeukemiaPromote immunityLymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing. Our analysis unveiled lymphocyte cytosolic protein 1 (LCP1), a lymphocyte-specific target that is highly expressed in CLL. LCP1 plays a critical role in B-cell biology by crosslinking F-actin filaments, thereby solidifying cytoskeletal structures and providing a scaffold for critical signaling pathways. Small interfering RNA knockdown of LCP1 blocked migration toward CXCL12 in transwell assays and to bone marrow in an in vivo xenotransplant model, confirming a role for LCP1 in leukemia migration. In addition, we identify LCP1 as a membrane-associated target in CLL with confirmed pathogenic significance.
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LCP1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LCP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0830.863
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5190.825
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2370.894
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0120.975
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1030.961
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1610.954
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.40.539
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6320.769
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1650.945
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.60.402
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.3780.662
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0830.61
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LCP1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LCP1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LCP1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LCP1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LCP1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LCP1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LCP1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLCP1
Namelymphocyte cytosolic protein 1 (L-plastin)
Aliases PLS2; CP64; L-PLASTIN; LC64P; plastin 2; HEL-S-37; L-plastin (Lymphocyte cytosolic protein 1) (LCP-1) (LC64P ......
Chromosomal Location13q14.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LCP1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.